Fortress Biotech vs Verrica Pharmaceuticals
FBIO and VRCA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FBIO and VRCA compare
Fortress Biotech and Verrica Pharmaceuticals are about the same size, with market caps of $69.1M and $61.2M.
Fortress Biotech grew revenue faster over the last twelve months (12.3% versus −25.7% for Verrica Pharmaceuticals).
Fortress Biotech keeps more of each dollar of sales as profit, with a net margin of 143% compared with −189% at Verrica Pharmaceuticals.
Fortress Biotech scores higher on the StockData Score (9 against 4 for Verrica Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FBIO | VRCA |
|---|---|---|
| Size and price | ||
| Market cap | $69.1M | $61.2M |
| Share price | $1.88 | $3.56 |
| Change, 1 year | −28.2% | −6.8% |
| Change, 5 years | −95.9% | −96.9% |
| Beta (5Y) | 1.37 | 1.08 |
| Employees | 78 | 76 |
| StockData Score | ||
| Total score | 9 (better) | 4 |
| Valuation score | 1 | 1 |
| Growth score | 1 | 1 |
| Performance score | 3 (better) | 1 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.0× (better) | 2.7× |
| P/B | 0.4× | – |
| Growth | ||
| Revenue growth (TTM) | 12.3% (better) | −25.7% |
| Revenue growth, 5Y average | 6.8% | – |
| Net income growth (TTM) | 2411% | – |
| Profitability | ||
| Gross margin | 66.2% | – |
| Operating margin | −42.5% (better) | −184% |
| Net margin | 143% (better) | −189% |
| Return on equity | 92.8% | – |
| Return on invested capital | −132% | – |
| Financial health | ||
| Debt / equity | 0.11 | – |
| Interest coverage | −3.2× (better) | −21.9× |
| Current ratio | 2.93 (better) | 1.66 |
| Altman Z-score | −2.25 (better) | −14.33 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 15.9% | 27.1% |
| Held by insiders | 31.6% | – |
| Insider net buying, 12 months | – | $211K |
Go deeper
- FBIO stock overview
- FBIO income statement
- FBIO valuation and score
- VRCA stock overview
- VRCA income statement
- VRCA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.